Clinical safety rating: caution
Animal studies have proved adverse effects but may be safe for humans
Venlafaxine is a serotonin-norepinephrine reuptake inhibitor (SNRI). It inhibits the reuptake of serotonin and norepinephrine at presynaptic neurons, increasing their concentrations in the synaptic cleft. At high doses, it also weakly inhibits dopamine reuptake.
| Metabolism | Primarily metabolized by CYP2D6 to its active metabolite O-desmethylvenlafaxine. Also metabolized by CYP3A4 to a lesser extent. Venlafaxine and its metabolites are excreted via kidneys. |
| Excretion | Renal excretion of parent drug and metabolites accounts for ~87% of elimination; unchanged venlafaxine: ~5%, active metabolite O-desmethylvenlafaxine: ~29%, other metabolites: ~53%; fecal excretion: <2%. |
| Half-life | Venlafaxine: 5 ± 2 h; O-desmethylvenlafaxine: 11 ± 2 h; clinical context: extended half-life of metabolite contributes to sustained effect, requiring steady-state in ~3 days. |
| Protein binding | Venlafaxine: 27% bound to plasma proteins (primarily albumin); O-desmethylvenlafaxine: 30% bound. |
| Volume of Distribution | Venlafaxine: 7.5 ± 3.7 L/kg; large Vd indicates extensive tissue distribution, including brain penetration. |
| Bioavailability | Oral immediate-release: ~40-45% (due to first-pass metabolism); extended-release: similar absolute bioavailability; food does not significantly affect absorption. |
| Onset of Action | Oral immediate-release: therapeutic effect may begin within 1-2 weeks, but full response often takes 4-8 weeks; no IV formulation; delayed absorption with extended-release (max effect similar). |
| Duration of Action | Oral immediate-release: dosing every 8-12 hours; extended-release: once-daily dosing; clinical note: withdrawal symptoms may occur upon abrupt cessation due to short half-life. |
| Molecular Weight | 277.4 |
Immediate-release: 75 mg/day orally in divided doses (2-3 times daily); may increase by up to 75 mg/day at intervals of at least 4 days. Maximum: 375 mg/day. Extended-release: 75 mg once daily; may increase by up to 75 mg/day at intervals of at least 4 days. Maximum: 225 mg/day.
| Renal impairment | GFR 30-89 mL/min: Reduce total daily dose by 25-50%. GFR <30 mL/min: Reduce total daily dose by 50% and increase dosing interval if needed. Hemodialysis: Administer after dialysis session. |
| Liver impairment | Child-Pugh Class A: Reduce total daily dose by 25%. Child-Pugh Class B/C: Reduce total daily dose by 50%. |
| Pediatric use | Children and adolescents (≥6 years): Begin at 37.5 mg/day orally (immediate-release in divided doses or extended-release once daily); titrate up to 75 mg/day. Maximum: 225 mg/day. Weight-based data insufficient; use clinical judgment. |
| Geriatric use | Start at 37.5 mg/day (immediate-release in divided doses or extended-release once daily); titrate slowly. Maximum: 225 mg/day. Monitor for hypertension and hyponatremia. |
| 1st trimester | Limited human data; animal studies have shown adverse effects. Use only if potential benefit justifies risk. May increase risk of cardiovascular malformations (e.g., ventricular septal defect) at high doses. |
| 2nd trimester | Monitor for maternal side effects; no specific fetal risks identified beyond general caution. Use if clearly needed. |
| 3rd trimester | Risk of persistent pulmonary hypertension of the newborn (PPHN) and neonatal adaptation syndrome (irritability, feeding difficulties, respiratory distress). Taper if possible before delivery. |
Clinical note
SNRI used for depression, anxiety, and panic disorder. Large cohort data are largely reassuring for MCM but some studies suggest a small increase in risk of cardiovascular defects and postpartum hemorrhage. More prominent neonatal withdrawal syndrome than SSRIs due to norepinephrine reuptake inhibition — neonatal adaptation syndrome may be more severe and longer lasting. Pulmonary hypertension of the newborn (PPHN) risk similar to SSRIs (small absolute risk).
| Placental transfer | Crosses the placenta readily; cord blood concentration approximately 70-100% of maternal serum concentration. |
■ FDA Black Box Warning
Increased risk of suicidal thinking and behavior in children, adolescents, and young adults taking antidepressants. Monitor closely for clinical worsening, suicidality, or unusual changes in behavior.
| Common Effects | Nausea Vomiting Dizziness Insomnia difficulty in sleeping Decreased appetite Anxiety Constipation Increased sweating Sexual dysfunction |
| Serious Effects |
Concurrent use with MAO inhibitors or within 14 days of MAOI discontinuationHypersensitivity to venlafaxine or any excipients
| Precautions | Serotonin syndrome, elevated blood pressure, narrow-angle glaucoma, activation of mania/hypomania, seizures, hyponatremia, abnormal bleeding, sexual dysfunction, discontinuation syndrome, increased cholesterol levels. |
| Food/Dietary | Avoid grapefruit and grapefruit juice as they inhibit CYP3A4, increasing venlafaxine levels. High-tyramine foods (e.g., aged cheeses, cured meats) are not contraindicated but use caution in patients also taking MAOIs. St. John's Wort may cause serotonin syndrome and should be avoided. |
Loading safety data…
| Breastfeeding | Present in breast milk in moderate amounts; infant serum levels are variable. Reported infant side effects include irritability, poor feeding, and somnolence. Monitor infant for signs of toxicity, especially in newborns or preterm infants. Alternative antidepressants may be preferred. |
| Lactation Rating | L3 (Moderately Safe) |
| Teratogenic Risk | First trimester: Data from large cohort studies do not show a significantly increased risk of major congenital malformations overall, but a small increased risk of cardiovascular defects (primarily ventricular septal defects) has been reported (adjusted OR ~1.3-1.5). Second trimester: No specific structural teratogenicity; however, poorly controlled maternal depression is associated with adverse obstetric outcomes. Third trimester (late): Exposure may increase risk of persistent pulmonary hypertension of the newborn (PPHN; absolute risk ~3 per 1000 vs 1-2 per 1000) and neonatal adaptation syndrome (including respiratory distress, feeding difficulties, irritability, tremors, and jitteriness) occurring in up to 30% of neonates. |
| Fetal Monitoring | Maternal: Monitor blood pressure regularly (venlafaxine can elevate BP), thyroid function, and signs of serotonin syndrome (especially if polypharmacy). Fetal/neonatal: Third trimester ultrasound for growth and amniotic fluid volume; assess for neonatal adaptation syndrome at birth using standardized scoring (e.g., Finnegan or modified tools). Monitor for PPHN signs (tachypnea, cyanosis, respiratory distress) in the first 24-48 hours postpartum. |
| Fertility Effects | In animal studies, venlafaxine did not impair fertility at clinically relevant doses. In humans, limited data suggest no major effect on female fertility; however, hyperprolactinemia (rare) can occur with SSRIs/SNRIs, potentially affecting ovulation. In males, case reports of erectile dysfunction and delayed ejaculation may indirectly affect fertility. Overall, no strong evidence of direct impairment of fertility. |
| Clinical Pearls | Monitor blood pressure regularly; dose-dependent hypertension is common at >300 mg/day. Venlafaxine has a short half-life; abrupt discontinuation can cause withdrawal syndrome. For patients with anxiety, start at 37.5 mg daily to minimize activation. Consider therapeutic drug monitoring in non-responders: target parent+metabolite level 200-400 ng/mL. |
| Patient Advice | Take with food to reduce nausea. · Do not stop suddenly; taper over 2-4 weeks to avoid withdrawal symptoms like dizziness, nausea, or electric shock sensations. · Full therapeutic effect may take 2-4 weeks for depression, up to 8 weeks for anxiety. · May cause drowsiness or insomnia; take in the morning if activating, at night if sedation occurs. · Avoid alcohol as it can worsen CNS effects. · Report new or worsening suicidal thoughts, especially in young adults. |